




UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NUMBER	FILING OR 371 (c) DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/697,912	10/30/2003	Chanchal Sadhu	27866/36170D

04743  
MARSHALL, GERSTEIN & BORUN LLP  
6300 SEARS TOWER  
233 S. WACKER DRIVE  
CHICAGO, IL 60606



CONFIRMATION NO. 2691

FORMALITIES LETTER



\*OC000000012919572\*

Date Mailed: 06/14/2004

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
DISCLOSURES**

*Filing Date Granted*

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).


- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

**For questions regarding compliance to these requirements, please contact:**

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

Replies should be mailed to: Mail Stop Missing Parts  
Commissioner for Patents  
P.O. Box 1450  
Alexandria VA 22313-1450

*A copy of this notice MUST be returned with the reply.*



Customer Service Center

Initial Patent Examination Division (703) 308-1202


PART 2 - COPY TO BE RETURNED WITH RESPONSE



PATENT  
Attorney Docket No: 27866/36170D

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Sadhu, et al.  
Serial No: 10/697,912  
Filed: October 30, 2003  
For: Inhibitors of Human  
Phosphatidylinositol 3-Kinase Delta  
Group Art Unit: TBD  
Examiner: TBD

) I hereby certify that this paper is being deposited  
) with the United States Postal Service as first class  
) mail, postage prepaid, in an envelope addressed to:  
) Mail Stop Missing Parts, Commissioner for  
) Patents, P.O. Box 1450, Alexandria, VA 22313-  
) 1450 on this date:  
) July 20, 2004  
)   
) James J. Napoli, Reg. No. 32,361  
) Attorney for Applicants

**RESPONSE TO COMPLY WITH REQUIREMENTS FOR PATENT  
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR  
AMINO ACID SEQUENCE DISCLOSURES**

Mail Stop Missing Parts  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:


This paper is in response to the "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" dated June 14, 2004. A copy of the notice is attached.

Submitted herewith in response to the notice is a Request Under 37 C.F.R. § 1.821(e).

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN LLP

July 20, 2004

  
James J. Napoli, Reg. No. 32,361  
Attorney for Applicants  
6300 Sears Tower  
233 S. Wacker Drive  
Chicago, Illinois 60606-6357  
(312) 474-6300